drugset / Trial / NCT06190249
Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy of adjuvant adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin-2 (IL-2) after a nonmyeloablative lymphodepletion (NMA-LD) preparative regimen, followed by Pembrolizumab.
Timeline
- Start
- 2024-12-02
- Primary completion
- 2028-01
- Completion
- 2028-07
Outcome
Outcome not reported
Stopped (Enrollment): “Iovance withdrew support due to length of time required to meet accrual goal.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | — | — |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |
| Background | Natural Killer Cells | Cell therapy | — | Intravenous |